Compile Data Set for Download or QSAR

Found 22 hits Enz. Inhib. hit(s) with all data for entry = 8247   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
RAF proto-oncogene serine/threonine-protein kinase [Y340D,Y341D] (Homo sapiens (Human))	BDBM238347 (US9388165, 3) Show SMILES Cc1ccc(cc1NC(=O)c1cccc2c(N)nccc12)C(=O)Nc1cccc(c1)C(F)(F)F Show InChI InChI=1S/C25H19F3N4O2/c1-14-8-9-15(23(33)31-17-5-2-4-16(13-17)25(26,27)28)12-21(14)32-24(34)20-7-3-6-19-18(20)10-11-30-22(19)29/h2-13H,1H3,(H2,29,30)(H,31,33)(H,32,34)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.80	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description The compounds prepared in Examples were tested for inhibitory activities against three subtypes of RAF, i.e. RAF1 Y340D Y341D, BRAF normal type and B...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340D,Y341D] (Homo sapiens (Human))	BDBM238345 (US9388165, 1) Show SMILES Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1NC(=O)c1cccc2c(N)nccc12 Show InChI InChI=1S/C25H19F3N4O2/c1-14-8-9-17(31-23(33)15-4-2-5-16(12-15)25(26,27)28)13-21(14)32-24(34)20-7-3-6-19-18(20)10-11-30-22(19)29/h2-13H,1H3,(H2,29,30)(H,31,33)(H,32,34)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	6.10	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description The compounds prepared in Examples were tested for inhibitory activities against three subtypes of RAF, i.e. RAF1 Y340D Y341D, BRAF normal type and B...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340D,Y341D] (Homo sapiens (Human))	BDBM238349 (US9388165, 6) Show SMILES CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(NC(=O)c4cccc5c(NC(C)(C)C)nccc45)c3)cc2C(F)(F)F)CC1 Show InChI InChI=1S/C36H41F3N6O2/c1-6-44-16-18-45(19-17-44)22-25-12-13-26(21-30(25)36(37,38)39)41-33(46)24-11-10-23(2)31(20-24)42-34(47)29-9-7-8-28-27(29)14-15-40-32(28)43-35(3,4)5/h7-15,20-21H,6,16-19,22H2,1-5H3,(H,40,43)(H,41,46)(H,42,47)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	6.40	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description The compounds prepared in Examples were tested for inhibitory activities against three subtypes of RAF, i.e. RAF1 Y340D Y341D, BRAF normal type and B...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340D,Y341D] (Homo sapiens (Human))	BDBM238348 (US9388165, 4) Show SMILES Cc1ccc(cc1NC(=O)c1cccc2c(N)nccc12)C(=O)Nc1ccc(Cl)c(c1)C(F)(F)F Show InChI InChI=1S/C25H18ClF3N4O2/c1-13-5-6-14(23(34)32-15-7-8-20(26)19(12-15)25(27,28)29)11-21(13)33-24(35)18-4-2-3-17-16(18)9-10-31-22(17)30/h2-12H,1H3,(H2,30,31)(H,32,34)(H,33,35)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	10.7	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description The compounds prepared in Examples were tested for inhibitory activities against three subtypes of RAF, i.e. RAF1 Y340D Y341D, BRAF normal type and B...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340D,Y341D] (Homo sapiens (Human))	BDBM238346 (US9388165, 2) Show SMILES Cc1ccc(cc1NC(=O)c1cccc2c(NC(C)(C)C)nccc12)C(=O)Nc1cccc(c1)C(F)(F)F Show InChI InChI=1S/C29H27F3N4O2/c1-17-11-12-18(26(37)34-20-8-5-7-19(16-20)29(30,31)32)15-24(17)35-27(38)23-10-6-9-22-21(23)13-14-33-25(22)36-28(2,3)4/h5-16H,1-4H3,(H,33,36)(H,34,37)(H,35,38)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description The compounds prepared in Examples were tested for inhibitory activities against three subtypes of RAF, i.e. RAF1 Y340D Y341D, BRAF normal type and B...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340D,Y341D] (Homo sapiens (Human))	BDBM238350 (US9388165, 8) Show SMILES Cc1ccc(cc1NC(=O)c1cccc2c(NC(C)(C)C)nccc12)C(=O)Nc1ccccc1 Show InChI InChI=1S/C28H28N4O2/c1-18-13-14-19(26(33)30-20-9-6-5-7-10-20)17-24(18)31-27(34)23-12-8-11-22-21(23)15-16-29-25(22)32-28(2,3)4/h5-17H,1-4H3,(H,29,32)(H,30,33)(H,31,34)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	20.5	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description The compounds prepared in Examples were tested for inhibitory activities against three subtypes of RAF, i.e. RAF1 Y340D Y341D, BRAF normal type and B...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
Serine/threonine-protein kinase B-raf [V600E] (Homo sapiens (Human))	BDBM238345 (US9388165, 1) Show SMILES Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1NC(=O)c1cccc2c(N)nccc12 Show InChI InChI=1S/C25H19F3N4O2/c1-14-8-9-17(31-23(33)15-4-2-5-16(12-15)25(26,27)28)13-21(14)32-24(34)20-7-3-6-19-18(20)10-11-30-22(19)29/h2-13H,1H3,(H2,29,30)(H,31,33)(H,32,34)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	61	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description In a similar manner to Experimental Example 1, the % inhibitory activity (concentration of the compound 1.0 μM) and the IC50 values of the inven...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
Platelet-derived growth factor receptor beta (Homo sapiens (Human))	BDBM238345 (US9388165, 1) Show SMILES Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1NC(=O)c1cccc2c(N)nccc12 Show InChI InChI=1S/C25H19F3N4O2/c1-14-8-9-17(31-23(33)15-4-2-5-16(12-15)25(26,27)28)13-21(14)32-24(34)20-7-3-6-19-18(20)10-11-30-22(19)29/h2-13H,1H3,(H2,29,30)(H,31,33)(H,32,34)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	66	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description In a similar manner to Experimental Example 1, the % inhibitory activity (concentration of the compound 1.0 μM) and the IC50 values of the inven...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
Serine/threonine-protein kinase B-raf (Homo sapiens (Human))	BDBM238345 (US9388165, 1) Show SMILES Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1NC(=O)c1cccc2c(N)nccc12 Show InChI InChI=1S/C25H19F3N4O2/c1-14-8-9-17(31-23(33)15-4-2-5-16(12-15)25(26,27)28)13-21(14)32-24(34)20-7-3-6-19-18(20)10-11-30-22(19)29/h2-13H,1H3,(H2,29,30)(H,31,33)(H,32,34)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	87	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description In a similar manner to Experimental Example 1, the % inhibitory activity (concentration of the compound 1.0 μM) and the IC50 values of the inven...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340D,Y341D] (Homo sapiens (Human))	BDBM238351 (US9388165, 11) Show SMILES Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(NC(=O)c3cccc4c(N)nccc34)c2)cc(c1)C(F)(F)F Show InChI InChI=1S/C29H23F3N6O2/c1-16-6-7-18(10-25(16)37-28(40)24-5-3-4-23-22(24)8-9-34-26(23)33)27(39)36-20-11-19(29(30,31)32)12-21(13-20)38-14-17(2)35-15-38/h3-15H,1-2H3,(H2,33,34)(H,36,39)(H,37,40)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	94.8	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description The compounds prepared in Examples were tested for inhibitory activities against three subtypes of RAF, i.e. RAF1 Y340D Y341D, BRAF normal type and B...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340D,Y341D] (Homo sapiens (Human))	BDBM238352 (US9388165, 14) Show SMILES Cc1ccc(NC(=O)Nc2cccc(c2)C(F)(F)F)cc1NC(=O)c1cccc2c(N)nccc12 Show InChI InChI=1S/C25H20F3N5O2/c1-14-8-9-17(32-24(35)31-16-5-2-4-15(12-16)25(26,27)28)13-21(14)33-23(34)20-7-3-6-19-18(20)10-11-30-22(19)29/h2-13H,1H3,(H2,29,30)(H,33,34)(H2,31,32,35)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	108	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description The compounds prepared in Examples were tested for inhibitory activities against three subtypes of RAF, i.e. RAF1 Y340D Y341D, BRAF normal type and B...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340D,Y341D] (Homo sapiens (Human))	BDBM50396483 (PLX-4032 | RG 7204 | Ro 5185426 | US10570155, Vemu...) Show SMILES CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F Show InChI InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	Purchase DrugBank MCE PC cid PC sid PDB UniChem Similars	US Patent	n/a	n/a	128	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description The compounds prepared in Examples were tested for inhibitory activities against three subtypes of RAF, i.e. RAF1 Y340D Y341D, BRAF normal type and B...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM238345 (US9388165, 1) Show SMILES Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1NC(=O)c1cccc2c(N)nccc12 Show InChI InChI=1S/C25H19F3N4O2/c1-14-8-9-17(31-23(33)15-4-2-5-16(12-15)25(26,27)28)13-21(14)32-24(34)20-7-3-6-19-18(20)10-11-30-22(19)29/h2-13H,1H3,(H2,29,30)(H,31,33)(H,32,34)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	261	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description In a similar manner to Experimental Example 1, the % inhibitory activity (concentration of the compound 1.0 μM) and the IC50 values of the inven...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
Platelet-derived growth factor receptor alpha (Homo sapiens (Human))	BDBM238345 (US9388165, 1) Show SMILES Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1NC(=O)c1cccc2c(N)nccc12 Show InChI InChI=1S/C25H19F3N4O2/c1-14-8-9-17(31-23(33)15-4-2-5-16(12-15)25(26,27)28)13-21(14)32-24(34)20-7-3-6-19-18(20)10-11-30-22(19)29/h2-13H,1H3,(H2,29,30)(H,31,33)(H,32,34)	PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	393	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description In a similar manner to Experimental Example 1, the % inhibitory activity (concentration of the compound 1.0 μM) and the IC50 values of the inven...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
Fibroblast growth factor receptor 2 (Homo sapiens (Human))	BDBM238345 (US9388165, 1) Show SMILES Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1NC(=O)c1cccc2c(N)nccc12 Show InChI InChI=1S/C25H19F3N4O2/c1-14-8-9-17(31-23(33)15-4-2-5-16(12-15)25(26,27)28)13-21(14)32-24(34)20-7-3-6-19-18(20)10-11-30-22(19)29/h2-13H,1H3,(H2,29,30)(H,31,33)(H,32,34)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>2.50E+3	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description In a similar manner to Experimental Example 1, the % inhibitory activity (concentration of the compound 1.0 μM) and the IC50 values of the inven...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM238345 (US9388165, 1) Show SMILES Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1NC(=O)c1cccc2c(N)nccc12 Show InChI InChI=1S/C25H19F3N4O2/c1-14-8-9-17(31-23(33)15-4-2-5-16(12-15)25(26,27)28)13-21(14)32-24(34)20-7-3-6-19-18(20)10-11-30-22(19)29/h2-13H,1H3,(H2,29,30)(H,31,33)(H,32,34)	PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>2.50E+3	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description In a similar manner to Experimental Example 1, the % inhibitory activity (concentration of the compound 1.0 μM) and the IC50 values of the inven...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
Insulin-like growth factor 1 receptor (Homo sapiens (Human))	BDBM238345 (US9388165, 1) Show SMILES Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1NC(=O)c1cccc2c(N)nccc12 Show InChI InChI=1S/C25H19F3N4O2/c1-14-8-9-17(31-23(33)15-4-2-5-16(12-15)25(26,27)28)13-21(14)32-24(34)20-7-3-6-19-18(20)10-11-30-22(19)29/h2-13H,1H3,(H2,29,30)(H,31,33)(H,32,34)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>2.50E+3	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description In a similar manner to Experimental Example 1, the % inhibitory activity (concentration of the compound 1.0 μM) and the IC50 values of the inven...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human))	BDBM238345 (US9388165, 1) Show SMILES Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1NC(=O)c1cccc2c(N)nccc12 Show InChI InChI=1S/C25H19F3N4O2/c1-14-8-9-17(31-23(33)15-4-2-5-16(12-15)25(26,27)28)13-21(14)32-24(34)20-7-3-6-19-18(20)10-11-30-22(19)29/h2-13H,1H3,(H2,29,30)(H,31,33)(H,32,34)	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>2.50E+3	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description In a similar manner to Experimental Example 1, the % inhibitory activity (concentration of the compound 1.0 μM) and the IC50 values of the inven...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
Tyrosine-protein kinase ABL1 (Homo sapiens (Human))	BDBM238345 (US9388165, 1) Show SMILES Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1NC(=O)c1cccc2c(N)nccc12 Show InChI InChI=1S/C25H19F3N4O2/c1-14-8-9-17(31-23(33)15-4-2-5-16(12-15)25(26,27)28)13-21(14)32-24(34)20-7-3-6-19-18(20)10-11-30-22(19)29/h2-13H,1H3,(H2,29,30)(H,31,33)(H,32,34)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>2.50E+3	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description In a similar manner to Experimental Example 1, the % inhibitory activity (concentration of the compound 1.0 μM) and the IC50 values of the inven...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
Receptor tyrosine-protein kinase erbB-2 (Homo sapiens (Human))	BDBM238345 (US9388165, 1) Show SMILES Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1NC(=O)c1cccc2c(N)nccc12 Show InChI InChI=1S/C25H19F3N4O2/c1-14-8-9-17(31-23(33)15-4-2-5-16(12-15)25(26,27)28)13-21(14)32-24(34)20-7-3-6-19-18(20)10-11-30-22(19)29/h2-13H,1H3,(H2,29,30)(H,31,33)(H,32,34)	PDB MMDB UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>2.50E+3	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description In a similar manner to Experimental Example 1, the % inhibitory activity (concentration of the compound 1.0 μM) and the IC50 values of the inven...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
Epidermal growth factor receptor (Homo sapiens (Human))	BDBM238345 (US9388165, 1) Show SMILES Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1NC(=O)c1cccc2c(N)nccc12 Show InChI InChI=1S/C25H19F3N4O2/c1-14-8-9-17(31-23(33)15-4-2-5-16(12-15)25(26,27)28)13-21(14)32-24(34)20-7-3-6-19-18(20)10-11-30-22(19)29/h2-13H,1H3,(H2,29,30)(H,31,33)(H,32,34)	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>2.50E+3	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description In a similar manner to Experimental Example 1, the % inhibitory activity (concentration of the compound 1.0 μM) and the IC50 values of the inven...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair
Fibroblast growth factor receptor 1 (Homo sapiens (Human))	BDBM238345 (US9388165, 1) Show SMILES Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1NC(=O)c1cccc2c(N)nccc12 Show InChI InChI=1S/C25H19F3N4O2/c1-14-8-9-17(31-23(33)15-4-2-5-16(12-15)25(26,27)28)13-21(14)32-24(34)20-7-3-6-19-18(20)10-11-30-22(19)29/h2-13H,1H3,(H2,29,30)(H,31,33)(H,32,34)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>2.50E+3	n/a	n/a	n/a	n/a	n/a	n/a
HANMI PHARM. CO., LTD. US Patent					Assay Description In a similar manner to Experimental Example 1, the % inhibitory activity (concentration of the compound 1.0 μM) and the IC50 values of the inven...				US Patent US9388165 (2016) BindingDB Entry DOI: 10.7270/Q2F76BF9
					More data for this Ligand-Target Pair